Pharmaceutical and Medical Device Market Access in Key Asian Markets

VIEW THE VIDEO OF
OUR RECENT EVENT

Asian markets are increasingly the focus of pharmaceutical companies who are looking for new market opportunities beyond the traditional "rich-world" countries who are facing economic stagnation.Traditionally, more "mature" and higher income Asian markets such as Japan, Korea, Taiwan, Singapore and Hong Kong have been seen as the priority of pharma marketers, but now fast-developing, high-population countries such as China, India,Indonesia, Vietnam and Thailand, are increasingly the priority. Altogether, these developed and developing Asian countries cover around half of the world's population and are increasingly dominating pharmaceutical sales growth.

While Europe and North America are largely struggling to lift themselves out of a deep recession, constrained by high levels of public-sector debt, many developing countries are displaying impressive growth rates. Recently there have been several key developments in gaining market access to these countries, such as thedevelopments of innovative pricing strategies and market affordability based schemes which can give the pharma industry more alternatives to bring to the table when looking to launch products in these markets. A number of key pricing and reimbursement trends and reforms in the region are creating a complex and challenging yet very attractive environment.

Medical device and vaccine experts will be joining pharmaceutical colleagues and academics to give the complete and most updated picture of market access in theseexciting markets today and in the near future.

China is a good case study for other developing Asian markets and therefore, China will be a large focus of the second day of this event. China is currently going through a period of extensive healthcare reform with $124 billion planned to be invested by the end of 2011 and hundreds of billions of dollars budgeted further to 2020. The main aim is universal healthcare coverage by 2020, as well as the establishment of an extensive network of major hospitals and village clinics and the prioritization of primary care and preventative healthcare systems to encourage a healthier population.Pharmaceutical reimbursement is also a major focus and with the upcoming changes in pharmaceutical pricing controls, value-assessment and reimbursement priorities for the Chinese market about to be announced, the industry is holding their collective breath in anticipation of how the changes will affect them directly today, and in the longer-term.

This event will bring together experts responsible for key Asian markets globally and locally to discuss how the current changing environments will impact on market access in these markets and as a result affect global strategies. This event will be particularly focused on those who consider these markets a priority worthy of further understanding. Participants will also learn how to ensure their products are demonstrating value in correct terms, to the right people in each market.

Why Attend?

• Gain an extensive understanding of the reimbursement process and levels of decision-making in key Asian markets.
• Evaluate how pricing and reimbursement will be affected under healthcare reform initiatives.
• Discover which therapeutic areas offer the most opportunities now and in the future.
• Prioritize your strategies based on developments regarding healthcare financing reform for these countries.
• Follow HTA development and acceptance trends with the APAC markets.
• Learn how market leaders design and implement market affordability based approaches for Asian markets.
• Discuss the suitability of innovative reimbursement models: Which markets are ready for this?
• Read the stakeholder map and understand their priorities.
• Listen to case study examples of products recently launched with key learning points for the industry.
• Discover how much the Asian middle classes will affect the demand and affordability for pharmaceuticals.
• Urbanization in Emerging Asian Markets: What initiatives are being taken to improve healthcare in rural areas?

Who Will Benefit?

VPs, Directors, and Senior Managers at a Global, Emerging Markets and Regional levels of:
Market Access, Pricing & Reimbursement, Health Economics & Outcomes, Government & Stakeholder Relations, Regulatory Affairs, Medical Affairs, Marketing, Therapy Area Heads.

Solution providers & consultants:
CEOs, Business Development, Senior Consultants, Regional Heads

Plus:
Independent Academics, Health Economists, Health Technology Assessors, Government Officials, Public & Private Healthcare Providers, Senior Doctors & Patient Representatives

Your Prestigious Speaker Panel